Original document(6 pages)  中文版
    Disclosed is a Chinese medicinal compound prescription for treating chloasma, which comprises dahurian angelica root 1-10%, giant typhonium tuber 1-10%, bletilla striata 1-10%, root of balloonflower 1-15%, ledebouriella root 1-20%, Schizonepeta tenuifolia 1-10%, Chinese angelica root 1-15%, cinnamon twig 1-15%, poria cocos wolf 1-25%, red peony root 1-15%, root bark of tree peony 1-15%, peach kernel 1-35%, Loranthus mulberry mistletoe 1-15%, radix salvia miltiorrhiza 1-15%, rhizome of Sichuan lovage 1-10%, dried orange peel 1-20%, nutgrass flatsedge rhizome 1-10%, safflower 1-10%, licorice root 1-10%, and earthworm 1-10%.
Application Number
申请号
200410073563 Application Date
申请日
2004.12.31
Title 名称 Chinese medicinal compound prescription for treating chloasma
Publication Number
公开号
1799607 Publication Date
公开日
2006.07.12
Approval Pub. Date Granted Pub. Date
International Classification 分类号 A61K36/898,A61K36/9066,A61P17/00,A61P17/16,A61K35/64
Applicant(s) Name
申请人
Zhang Hengzhao
Address 地址 710077
Inventor(s) Name 发明人
Attorney & Agent 代理人 bao yanbeng

  
Method for designing chess board
Health medicated wine and its preparation method
Application of essence-supplementing deer essence in preparation of medicine for treating prostate diseases
Soft capsule formulation containing gastrodia tuber medicinal composition and preparation method thereof
Bone-strengthening herbal medicinal wine and its preparation method
Chinese medicinal preparation for treating diziness and preparation process thereof
Novel drug administering route of 'Qu Gan Re' injection, its preparation process and novel indications
Chinese medicine for treating damp heat arthralgia and its preparation method
Chinese traditional medicine composition for treating liver and kidney diseases and preparation method thereof
Pharmaceutical composition for treating hysteromyoma and production method thereof
Google
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.